ICH E6(R3) replaces the 2016 R2 text with a principles-based, risk-proportionate framework, and the EU has already put the first part into effect, with the second following in January 2027.
Where the guideline stands in the EU
According to EMA, the principles and Annex 1 (interventional clinical trials) have been in effect since 23 July 2025. Annex 2, covering non-traditional interventional trials such as pragmatic and decentralised trials and trials using real-world data sources, was adopted by CHMP in June 2026 and takes effect on 15 January 2027. A consolidated guideline has also been published with the same January 2027 effective date. E6(R3) therefore already governs new thinking on GCP in Europe, and the remaining step is Annex 2.
A new structure
- Principles: a short set of interdependent principles meant to be read together.
- Annex 1: detailed expectations for interventional trials, with appendices on applying the principles.
- Annex 2: additional considerations for trial designs and data sources that depart from the traditional site-based model.
Where R2 was prescriptive about processes, R3 sets outcomes and expects sponsors to justify how they are achieved.
What changes in practice
- Proportionality: trial conduct should be fit for purpose, with effort focused on what matters to participant protection and the reliability of results.
- Quality by design: building on ICH E8(R1), quality is planned in from the start, with critical-to-quality factors identified early and interested parties engaged in proportion to risk.
- Innovation: new language accommodates technology and operational models, including decentralised elements.
- Transparency: registration and reporting of results are promoted.
- Informed consent: additional guidance strengthens the consent process.
The guideline also sets out responsibilities for sponsors, investigators and other parties, and addresses areas such as oversight of service providers, data governance and computerised systems. Read the consolidated text for the exact wording of these provisions.
What sponsors should review now
- Monitoring and quality management procedures, to check they are risk-proportionate and not simply a fixed schedule of visits.
- Identification of critical-to-quality factors at protocol design stage.
- CRO and vendor oversight, including documented responsibilities and quality agreements.
- Computerised systems used in trials, including validation and data governance.
- Informed consent materials and processes.
- Training for study teams and investigators on the new framework.
Preparing for Annex 2
Sponsors planning decentralised, pragmatic or real-world-data-based studies should start mapping their designs against Annex 2 before it applies, since it will shape expectations on data sources, participant oversight and local healthcare provider involvement.
Related reading
- Clinical Trial Applications in Greece: CTIS, Timelines and the FAST-EU Pilot
- Document Control in a Pharmaceutical QMS: Hierarchy, Versions and the Draft EU Chapter 4
- Data Integrity and ALCOA+: Turning Audit Trail Review into a Real Control
How PQRA helps
PQRA helps sponsors and investigators in Greece and the EU compare their SOPs and trial documentation with E6(R3), plan quality by design for new protocols, strengthen vendor oversight and prepare for the January 2027 Annex 2 date.
Ready to talk it through? Contact the PQRA team.


No responses yet